Pharmamel continues to advance towards its entry into the pharmaceutical and stock markets, having secured 55% of its goal in the Pre-IPO financing round through Capital Cell. Over 214 investors have contributed over 1,100,000 euros for the development of the innovative intravenous drug against sepsis. In addition, the Granada-based biotechnology company continues to make progress in pharmaceutical development, which is already in phase III.
Pharmamel, the innovative biotechnology company born out of the University of Granada, is breaking barriers on its path to the market, both pharmaceutical and stock, already achieving 55% of the target in its current Pre-IPO capital expansion round. Through the leading biotechnology investment platform, Capital Cell, over 214 investors have bet on Pharmamel, contributing over 1,100,000 euros to boost the development of its revolutionary drug against sepsis.
This is a key moment for Pharmamel and for any investor interested in being part of a project with global impact. The innovative intravenous treatment for sepsis, backed by years of research and two successful phase II clinical trials, is closer than ever to transforming the medical landscape in the treatment of this disease. The company has initiated preparations for the phase IIB/III clinical trial in Europe and the United States, representing a significant step towards implementing this solution in clinical practice.
This capital expansion campaign offers an exclusive opportunity for investors and professionals who wish to join Pharmamel before its IPO. The investment is simple, safe, and regulated, through a reliable platform, allowing investors to be part of a company with a promising future in the global healthcare sector.
Pharmamel is not only making progress in its financing, but is also in talks with major names in the pharmaceutical industry both in Europe and nationally. These strategic negotiations aim to secure key allies who can support Pharmamel in the large-scale manufacturing and distribution of its innovative drug, thus boosting its international expansion.
Additionally, Pharmamel has been selected as a finalist Scaleup in the prestigious Al Andalus Innovation Venture 2024, an event that brings together the best entrepreneurs, investors, and corporations. This recognition not only highlights the quality and potential of Pharmamel’s biotechnological and business project, but also opens new doors for strategic alliances and growth opportunities.
Pharmamel is in a unique position to transform the way sepsis is treated, one of the leading causes of hospital mortality worldwide. With the support of new investors, the company is one step closer to bringing the innovative intravenous melatonin treatment to the market, saving lives and creating value.
The capital expansion campaign remains open on the CNMV-regulated Capital Cell platform, accessible to individuals and professionals through the following link: [https://capitalcell.com/campaign/pharmamel-2024/].
Videos:
– Dr. Dario Acuña explains Why is melatonin useful against sepsis?
– Pharmamel new Pre-IPO capital expansion round
– Dr. Germaine Escames presents the promising results of the phase II clinical trials.
via: MiMub in Spanish
